Methoxysarin ointment 0.3% is mainly used for local photochemical treatment of psoriasis and vitiligo, and must strictly follow the indications and medication standards for special populations. The following are specific classification instructions.

1. Adapt to the population

(1) Psoriasis patients: Suitable for adjuvant treatment of plaque psoriasis, with the assistance of doctor guided ultraviolet irradiation, and a single medication area not exceeding 10% of the body surface.

(2) Vitiligo patients: Used for the multi-color treatment of stable localized skin lesions, the limb area needs to extend the light exposure time to improve the efficacy.

2. Taboo population

(1) Patients with photosensitive diseases, such as lupus erythematosus and photodermatitis, should not use it as it may worsen the condition or induce phototoxic reactions.

(2) Individuals with a history of skin tumors: contraindicated as ultraviolet radiation may activate potential cancer cells.

3. Medication for special populations

(1) Pregnant women: Animal experiments have shown potential embryotoxicity, and should only be used during pregnancy when the benefits significantly outweigh the risks.

(2) Breastfeeding women: It is recommended to pause breastfeeding during treatment to avoid drugs from entering breast milk after being absorbed through the skin.

(3) Children under 12 years old lack safety data and require individualized medication after evaluation by a doctor.

(4) Elderly people: Weakened skin barrier function, need to reduce medication frequency and closely monitor skin reactions.

4. Pre medication evaluation

(1) It is necessary to improve skin microscopy examination to exclude malignant lesions, test liver function, and perform photosensitivity tests.

(2) Individuals with a history of using photosensitive drugs should wait for 2 weeks before starting treatment to prevent the accumulation of side effects.

5. Key points of medication monitoring

(1) Pre treatment assessment: Complete dermatological examination and liver function testing are required.

(2) Monitoring during treatment: Observe skin reactions after each medication and stop immediately if blisters appear.

(3) Post treatment protection: Strictly avoid light for 48 hours to prevent the accumulation of phototoxicity.